Formycon AG (FSB: FYB, Prime Standard) plans to publish its financial results for the 2025 fiscal year on April 22, 2026. The management board will discuss the company’s development, key financial figures, and provide an outlook for the 2026 fiscal year during a conference call scheduled for Wednesday, April 22, 2026, at 3:00 PM (CEST). The call, conducted in English, will be broadcast live and is accessible after registration at this registration link. Participants will receive a confirmation email with individual dial-in data. The presentation and audio broadcast can be accessed via the webcast link. Following a brief presentation, the management board will be available for analysts’ questions. The conference call will be recorded and subsequently accessible on the Formycon website at Formycon's publications page.
In the second quarter of 2026, Formycon representatives will attend several international investor conferences. On May 11–12, 2026, CFO Enno Spillner will participate in the Equity Forum Spring Conference in Frankfurt, Germany. On May 28, 2026, Formycon will publish its results for the first quarter of 2026, followed by a conference call and webcast with CEO Dr. Stefan Glombitza, CFO Enno Spillner, CBO Nicola Mikulcik, and CSO Dr. Andreas Seidl. From June 2–4, CFO Spillner will attend the Jefferies Global Healthcare Conference in New York City. On June 8, the management team will lead an mwb research Roundtable webcast. The Annual General Meeting is scheduled for June 10, 2026, at Haus der Bayerischen Wirtschaft in Munich. Finally, on June 18, CFO Spillner will attend the UBS Life Sciences Conference in London. The full financial calendar is available at Formycon's financial calendar.
These events underscore Formycon's commitment to transparency and engagement with the investment community as it advances its biosimilar pipeline. Formycon, a leading independent developer of high-quality biosimilars, focuses on therapies in ophthalmology, immunology, immuno-oncology, and other key disease areas. The company covers nearly the entire value chain from technical development through clinical trials to regulatory approval. For commercialization, Formycon relies on strong, long-term partnerships worldwide. With FYB201/ranibizumab and FYB202/ustekinumab, Formycon already has two biosimilars on the market. Another biosimilar, FYB203/aflibercept, has been approved by the FDA, EMA, and MHRA. Four pipeline candidates, including FYB208/dupilumab, are currently in development. Through its biosimilars, Formycon aims to provide broader patient access to highly effective and affordable medicines.
